INTRODUCTION
Notch signaling influences cell fate determination by modulating cell proliferation, differentiation, apoptosis, migration, and invasion 1 . The Notch family is composed of 4 Notch receptors (Notch-1−Notch-4), and 5 Notch ligands, including Jagged-1 (JAG-1), JAG-2, Delta-like-1, Delta-like-3, and Delta-like-4 2 . Notch activation results in the following mechanisms: proteolytic cleavage of the Notch receptor by a metalloprotease ADAM17; formation of the γ-secretase complex; and the subsequent release of the Notch intracellular domain (NICD), which is then translocated to the nucleus to activate specific target genes such as hes-1 [3] [4] [5] .
The pathologic activation of Notch signaling has been implicated in the pathogenesis of various malignancies and fibrotic diseases, such as systemic sclerosis and idiopathic pulmonary fibrosis [6] [7] [8] . The inhibition of Notch signaling has been adopted in clinical trials to treat several malignant tumors such as gastrointestinal neuroendocrine tumors, metastatic thyroid cancer, and advanced breast cancer 2 . Recent studies have demonstrated the anti-fibrotic effects of Notch signaling inhibition in vitro and genetic inhibition of Notch signaling in murine fibrosis models 9, 10 .
Transforming growth factor β1 (TGF-β1) is a principal fibrogenic cytokine that promotes the production of the extracellular matrix and tissue fibrosis 11 . The activation of the TGF-β signaling pathway is considered to be the main pathogenesis of fibrotic skin diseases such as keloids 11 .
There is evidence that the Notch signaling pathway exerts its effects via upstream or downstream signaling transduction of the TGF-β signaling pathway 6, 12 . A recent study
showed that NICD and hes-1 levels increased in skin fibroblasts stimulated by TGF-β in patients with systemic sclerosis 9, 10 . Inhibiting the activation of the Notch receptor attenuates TGF-β-induced α-smooth muscle actin expression 6 . The degree of expression was categorized as follows: 0, 0% positive; +, 1%∼19% positive; ++, 20%∼79% positive; and +++, 80%∼100% positive. NICD: Notch intracellular domain.
The role of the Notch signaling pathway in fibroproliferative skin diseases has not been fully elucidated. Therefore, the aim of this study was to investigate NICD expression in normal skin specimens and fibroproliferative skin diseases, including keloids, hypertrophic scars, morpheas, and dermatofibromas.
MATERIALS AND METHODS

Patients and skin biopsy specimens
This study was approved by the ethical committee of The Catholic University of Korea, and all patients signed an informed consent. The study was conducted according to the Declaration of Helsinki principles.
The following formalin-fixed, paraffin-embedded specimens were retrieved: 5 normal human tissues, 5 morpheas, 5 hypertrophic scars, 5 dermatofibromas, and 5 keloids. The clinical information of patients is described in Table 1 .
Immunohistochemistry
The specimens after fixation in 4% paraformaldehyde were embedded in paraffin for histological or immunohistochemical examinations. All immunohistochemical stainings were performed using a Dako Envision kit (Dako Cytomation Co., Glostrup, Denmark) according to the manufacturer's instructions, using a commercially available prediluted monoclonal antibody against the Notch-1 (Abcam) antigen at a 1 : 200 dilution. Immunohistochemical analysis was performed on samples (Table 1 , 2), and the degree of expression was semiquantitatively graded as follows: +, 1% to 19% positive; ++, 20% to 79% positive; +++, 80% to 100% positive. Two independent dermatopathologists scored the samples of 3 high-powered fields per section, and the average score was calculated. All statistical analyses were performed using SPSS software ver. 15.0.1 (SPSS Inc., Chicago, IL, USA).
RESULTS
Keloids and hypertrophic scars
NICD in keloid and hypertrophic scar fibroblasts showed moderate to high immunoreactivity; similar observations were noted in keratinocytes, endothelial cells, and immune cells (Fig. 1∼3 , Table 1 ). In contrast, the extracellular matrix did not express NICD in both tumors. The pattern of NICD expression showed diffuse immunoreactivity in almost all fibroblastic foci of keloids and hypertrophic scars (Fig. 1A, B) . Two patients presented recurrent keloids and hypertrophic scars after laser treatment and excision, respectively. Specimens from both these patients exhibited moderate expression of fibroblast NICDs. NICD expression patterns did not vary according to disease duration, site of lesion, and recurrence history.
Dermatofibromas
Dermatofibromas also showed a similar degree of immunoreactivity for NICD in the tumor cells as well as in keloids and hypertrophic scars (Fig. 1C, 2D , 2E, 3, Table  1 ). Moderate to high immunoreactivity for NICD was detected in the overlying epidermal proliferation but was not detected in the grenz zone (Fig. 1C) . The NICD expression pattern showed diffuse immunoreactivity in fibrohistiocytic proliferation arranged in a storiform pattern in dermatofibromas (Fig. 1C, 2D ). The proliferation of fibroblast-like spindle cells, histiocytes, and vessels were uniformly stained for NICD (Fig. 2D, E) .
Morpheas
NICD expression was generally low in morphea fibroblasts, whereas high expression was detected in keratinocytes and endothelial cells (Fig. 1D, 2F , 3, Table 1 ). Interestingly, inflammatory infiltrate in a specimen of early morphea lesion showed moderate immunoreactivity for NICD (Fig. 2G) . The intensity of the immunopositivity of NICD varied at varied with areas in the same specimens in morphea tissue.
Normal skin specimens
NICD expression was generally low or not detected in fibroblasts of normal control cells, but high expression was detected in keratinocytes of the epidermis, hair follicles, sebaceous and eccrine glands, and endothelial cells (Fig. 1E, 2H, 3 , Table 1 ). NICD was highly stained in the upper epidermal layer than in the basal layer (Fig. 1E) . Physiological perivascular infiltrating immune cells showed high expression of NICD (Fig. 2H) .
DISCUSSION
In the present study, NICD expression levels were determined by immunohistochemical analysis of normal skin, keloid, hypertrophic scar, morphea, and dermatofibroma specimens. Keloids and hypertrophic scars are considered to be fibroblastic or myofibroblastic tumors 13 . Keloid and hypertrophic scar specimens showed moderate to high expression of NICD. Dermatofibroma, a representative fibrohistiocytic tumor, also exhibited moderate to high NICD expression in all tumor components. NICD expression was generally low or not detected in normal fibroblasts, and fibroblasts from patients with morphea were strongly stained compared to the normal cells; however, the proportion of NICD-immunopositive cells in normal fibroblasts was much lower than that of keloids, hypertrophic scars, and dermatofibromas. In contrast, significant staining of NICD in fibroblasts was observed only in various fibroproliferative skin diseases, and the accumulation of NICD in keratinocytes and endothelial cells was also observed in fibroproliferative diseases as well as normal controls. The Notch signaling pathway is involved in the normal wound healing process by modulating keratinocytes, fibroblasts, and endothelial cells 14 . Keloids and hypertrophic scars have been considered to be aberrant wound healing consquences 11 . The significant upregulation of the NICD in keloid fibroblasts observed in the present study is consistent with previous studies 9, 10, 14 . Keloid fibroblasts express NICD-1 (54.5%), NICD-2 (38.6%), and JAG-1 at mRNA and protein levels 14 . The inhibition of Notch signaling via JAG-1 knockdown led to the inhibition of proliferation, migration, and invasion properties of keloid fibroblasts 14 . Dees et al. 9 reported that significant staining of NICD in keloid and hypertrophic scar fibroblasts was also observed in specimens from patients with systemic sclerosis. However, our results showed that the immunoreactivity for NICD in keloids and hypertrophic scars was much higher than that in morphea. These results may be attributed to the fact that the proliferative, migratory, and invasive potential of myofibroblasts and fibroblasts in keloids, hypertrophic scars, and dermatofibromas are higher than those in morphea. Although morphea is considered to be a localized form of scleroderma, it may have different immunopathological characteristics from systemic sclerosis. Interestingly, the perivascular inflammatory infiltrate from two patients with early stage morphea and one patient with hypertrophic scars showed moderate to high immunopositivity for NICD. Recent evidence suggests the role of immune cells in activation of the Notch signaling pathway in skin fibrosis 9, 10, 14 .
Infiltrating T cells prominently expressed the ligand JAG-1 in human systemic sclerosis and fibroblasts stimulated by recruited inflammatory cells that may release NICD, which transforms tumor cells to adopt invasive phenotypes 9 .
Keloid samples with abundant immune cells significantly expressed Notch-1 in fibroblasts, but samples with few immune cells showed minimal to no expression of Notch-1 in fibroblasts 14 . However, overall, all keloid fibroblasts were immunopositive for NICD, although there was little to no adjacent inflammatory infiltrate in our study. Furthermore, Notch-expressing immune cells were observed in normal control skins in this study. There must be a difference between the immune cell characteristics of normal control skin and of skin of patients with fibroproliferative diseases. Thus, the pro-fibrotic role of immune cells needs to be further investigated. NICD was constitutively expressed in normal keratinocytes of the epidermis, hair follicles, sebaceous gland endothelial cells, and immune cells. Notch signaling has been suggested to regulate epidermis and hair follicle homeostasis 15, 16 . All specimens in our study exhibited high expression of NICD, especially in the upper epidermal layer 15 , and Notch-1 was reported to regulate earlyand late-stage epidermal differentiation 16 . In contrast, the normal skin specimens used in the study by Dees et al. 9 did not show NICD expression in keratinocytes, endothelial cells, and immune cells. This discrepancy is thought to result from differences in methodologies. Thus, there are conflicting results regarding the effects of Notch-1 on skin carcinogenesis 2, 17 .
The epithelial-to-mesenchymal transition (EMT) is a serial process, which consists of a disassembly of epithelial adherence junctions, morphological changes of epithelial cells to myofibroblasts, degradation of basement membranes, and the migration and invasion of myofibroblasts 18 . EMT normally occurs during hair follicle development and the wound repair process, but it occurs excessively in the progression of cancer or pathological fibrotic conditions such as multiple sclerosis and keloids 6, 19 . This process leads to increased myofibroblast accumulation and scarring 11 . Recent evidence has shown that the Notch signaling pathway promotes EMT via interactions with the TGF-β signaling pathway in the kidney tubular epithelium 20 .
The Notch signaling pathway is known to modulate angiogenesis in normal tissues and tumors 15 , and the inhibition of Notch signaling showed anti-angiogenic effects in keloids 14 .
Morphea is considered to be a result of the inflammatory cascade following vascular injury 13 . Hypoxia, reactive oxygen species, and TGF-β1 are suggested to be profibrotic factors in various fibroproliferative skin diseases such as morpheas and keloids 5, 21, 22 . The Notch signaling molecules in dermal fibroblasts are stimulated by hypoxia 9,10 , reactive oxygen species, or elevated levels of HaRas and Ki-Ras 23 .
In conclusion, the significant immunoreactivity for the NICD was observed in various fibrotic skin diseases, especially in keloids. In contrast, normal skin keratinocytes, immune cells, and endothelial cells constitutively expressed NICD. Skin fibroblasts only expressed NICD under pathologically fibrotic conditions. These results suggest a pro-fibrotic role of the Notch signaling pathway in human skin fibrosis. Further studies are required to establish the functional role for the NICD at the molecular level in the development and progression skin fibrosis.
